NRXP logo

NRx Pharmaceuticals, Inc.

NRXP
Healthcare|Biotechnology|US
$2.38
+0.11 (+4.85%)
DCF Value
$0.70
Cash / Share
$0.71

About

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Stock Price

-10.9%(1Y)
1M
-17.6%
3M
-33.5%
6M
-22.7%
YTD
-12.2%
1Y
-6.3%
3Y
-33.1%
5Y
-96.5%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$103.0M
Employees29 (+867% YoY)
CEOJonathan C. Javitt
IPO DateDec 4, 2017
Beta2.07
52-Week Range$1.62 – $5.06
Avg Volume1,059,868
ExchangeNASDAQ
Websitenrxpharma.com

Ownership

Float86.4%
Shares Outstanding43.3M

Recent Insider Trades

ABRAMS MICHAEL SAWARD
Jul 28, 202675,000 shares
Javitt Jonathan CAWARD
Jul 28, 2026150,000 shares
Casper Joseph MichaelAWARD
Jan 27, 2026100,000 shares @ $2.39
Casper Joseph MichaelOTHER
Jan 27, 2026100,000 shares @ $2.39
Javitt Jonathan CAWARD
Apr 9, 2025125,000 shares @ $1.73

Peers

COEPCoeptis Therapeutics Holdings, Inc.
$38.6M
CUECue Biopharma, Inc.
$136.1M
EQEquillium, Inc.
$95.7M
HOWLWerewolf Therapeutics, Inc.
$49.1M
IOBTIO Biotech, Inc.
$885.7K
IPSCCentury Therapeutics, Inc.
$304.2M
KPTIKaryopharm Therapeutics Inc.
$1.2M
OTLKOutlook Therapeutics, Inc.
$106.2M

Recent News

NRx Pharmaceuticals (NASDAQ:NRXP) versus TherapeuticsMD (NASDAQ:TXMD) Head-To-Head Contrast
Nov 6, 2026 · defenseworld.net
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
Oct 30, 2026 · seekingalpha.com
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
Oct 30, 2026 · marketbeat.com
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
Oct 30, 2026 · globenewswire.com
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Oct 29, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:24 AM